Literature DB >> 17672886

Caudwell Xtreme Everest: a field study of human adaptation to hypoxia.

Mike Grocott, Alan Richardson, Hugh Montgomery, Monty Mythen.   

Abstract

Caudwell Xtreme Everest (CXE) is a large healthy volunteer field study investigating human adaptation to environmental hypoxia. More than 200 individuals were studied at sea-level and in four laboratories on the trek to Everest Base Camp (5,300 m). Fifteen physicians climbed high on Everest and continued the studies as they ascended; eight of these individuals reached the summit of Everest and succeeded in sampling arterial blood at 8,400 m on their descent. Core measurements included cardiopulmonary exercise testing, neuropsychological assessment, near infra-red spectroscopy of brain and exercising muscle, blood markers and daily recording of simple physiological variables. The goal of CXE is to further our understanding of human adaptation to cellular hypoxia, a fundamental mechanism of injury in critical illness, with the aim of improving the care of critically ill patients.

Entities:  

Mesh:

Year:  2007        PMID: 17672886      PMCID: PMC2206524          DOI: 10.1186/cc5921

Source DB:  PubMed          Journal:  Crit Care        ISSN: 1364-8535            Impact factor:   9.097


Caudwell Xtreme Everest (CXE) is a large, healthy volunteer field study investigating human adaptation to environmental hypoxia [1]. The project is organised by the Centre for Altitude Space and Extreme Environment Medicine (CASE Medicine) at University College London. During April and May 2007 more than 200 individuals were studied as they were progressively exposed to hypobaric hypoxia on the trek to Everest Base Camp at 5,300 m. Most of these individuals were volunteers who gave up their holidays to be participants in the study. The remainder was comprised of doctors and scientists, 15 of whom continued the studies as they ascended up to 8,000 m. Eight of these investigators reached the summit of Everest and on their descent took the first measurement of arterial oxygen levels above 8,000 m. So what is the relevance of CXE to intensive care medicine? Cellular hypoxia is a fundamental mechanism of injury in the critically ill [2,3]. Indeed, it is hard to think of a critically ill patient in whom cellular hypoxia, either local or generalized, is not present. Hypoxia may occur as either a cause of or as a consequence of a variety of critical illnesses. Hypoxia mediated cell death may lead to the generation of an inflammatory response. Systemic inflammation is associated with the development of cellular hypoxia caused by decreased tissue oxygen delivery associated with microcirculatory dysfunction. Cellular hypoxia may also be caused by alterations in cellular energy pathways and mitochondrial function, resulting in decreased ability to utilize available oxygen [2,3]. Although our dominant treatment paradigm revolves around maintenance of oxygen delivery to the cells, there are few data to guide the optimal level of inspired oxygen. Moreover, in some circumstances increasing oxygen delivery confers no benefit or may even cause harm; for example, elevating haemoglobin levels or 'optimization' of oxygen delivery to specific goals in established critical illness [4-6]. Might it be that variations in the cellular efficiency of oxygen metabolism account for some of the observed differences in outcome following critical illness? The high altitude physiology literature gives us an elegant general description of adaptation to environmental hypoxia built around the idea that maintenance of oxygen delivery to the tissues will allow normal cellular function [7]. However, to date none of these adaptations explain observed (and dramatic) differences in performance between individuals at altitude. Again, the possibility that observed differences are not accounted for by variations in elements of the dominant paradigm raises the possibility that an unmeasured factor or factors may be important. The core hypothesis that CXE is addressing is that variations in metabolic efficiency (relationship between oxygen uptake and work rate) may explain, at least in part, observed differences in individuals' abilities to adapt to hypoxia. If this is true, then it may be possible – by examining the genotype and phenotype of the 'rapid adaptors' – to identify mechanisms and thereby develop treatments to benefit the 'slow adaptors' [8-10]. The studies conducted in CXE involve a variety of techniques, including cardiopulmonary exercise testing on cycle ergo-meters using breath-by-breath expired gas analysis, neuropsychological assessment, near infrared spectroscopy of brain and exercising muscle, blood markers (inflammatory and neuroendocrine) and daily recording of simple physiological variables [1]. These measurements and many more were taken in London before departure, in four laboratories in Nepal on the ascent to Everest Base Camp, and in two laboratories high on Mount Everest. The next few years will see whether this new approach to investigating the pathogenesis of critical illness bears fruit.

Abbreviations

CXE = Caudwell Xtreme Everest.

Competing interests

The authors are all investigators in the CXE research group.

Authors' contributions

AR, MM, HM and MG were all involved in either (or all) of original drafting, review and redrafting of the mansucript.
  9 in total

1.  Early goal-directed therapy in the treatment of severe sepsis and septic shock.

Authors:  E Rivers; B Nguyen; S Havstad; J Ressler; A Muzzin; B Knoblich; E Peterson; M Tomlanovich
Journal:  N Engl J Med       Date:  2001-11-08       Impact factor: 91.245

2.  Angiotensin-converting-enzyme gene insertion/deletion polymorphism and response to physical training.

Authors:  H Montgomery; P Clarkson; M Barnard; J Bell; A Brynes; C Dollery; J Hajnal; H Hemingway; D Mercer; P Jarman; R Marshall; K Prasad; M Rayson; N Saeed; P Talmud; L Thomas; M Jubb; M World; S Humphries
Journal:  Lancet       Date:  1999-02-13       Impact factor: 79.321

3.  Performance at altitude and angiotensin I-converting enzyme genotype.

Authors:  G Tsianos; K I Eleftheriou; E Hawe; L Woolrich; M Watt; I Watt; A Peacock; H Montgomery; S Grant
Journal:  Eur J Appl Physiol       Date:  2004-12-01       Impact factor: 3.078

4.  Angiotensin converting enzyme insertion/deletion polymorphism is associated with susceptibility and outcome in acute respiratory distress syndrome.

Authors:  Richard P Marshall; Suzanne Webb; Geoffrey J Bellingan; Hugh E Montgomery; Babar Chaudhari; Robin J McAnulty; Steve E Humphries; Mike R Hill; Geoffrey J Laurent
Journal:  Am J Respir Crit Care Med       Date:  2002-09-01       Impact factor: 21.405

5.  Response of critically ill patients to treatment aimed at achieving supranormal oxygen delivery and consumption. Relationship to outcome.

Authors:  M A Hayes; E H Yau; A C Timmins; C J Hinds; D Watson
Journal:  Chest       Date:  1993-03       Impact factor: 9.410

6.  Early goal-directed therapy after major surgery reduces complications and duration of hospital stay. A randomised, controlled trial [ISRCTN38797445].

Authors:  Rupert Pearse; Deborah Dawson; Jayne Fawcett; Andrew Rhodes; R Michael Grounds; E David Bennett
Journal:  Crit Care       Date:  2005-11-08       Impact factor: 9.097

Review 7.  Bench-to-bedside review: potential strategies to protect or reverse mitochondrial dysfunction in sepsis-induced organ failure.

Authors:  Alessandro Protti; Mervyn Singer
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

Review 8.  High-altitude physiology and pathophysiology: implications and relevance for intensive care medicine.

Authors:  Michael Grocott; Hugh Montgomery; Andre Vercueil
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

Review 9.  Bench-to-bedside review: Cytopathic hypoxia.

Authors:  Mitchell P Fink
Journal:  Crit Care       Date:  2002-09-12       Impact factor: 9.097

  9 in total
  8 in total

1.  The effect of high-altitude on human skeletal muscle energetics: P-MRS results from the Caudwell Xtreme Everest expedition.

Authors:  Lindsay M Edwards; Andrew J Murray; Damian J Tyler; Graham J Kemp; Cameron J Holloway; Peter A Robbins; Stefan Neubauer; Denny Levett; Hugh E Montgomery; Mike P Grocott; Kieran Clarke
Journal:  PLoS One       Date:  2010-05-19       Impact factor: 3.240

2.  High-resolution optical functional mapping of the human somatosensory cortex.

Authors:  Stefan P Koch; Christina Habermehl; Jan Mehnert; Christoph H Schmitz; Susanne Holtze; Arno Villringer; Jens Steinbrink; Hellmuth Obrig
Journal:  Front Neuroenergetics       Date:  2010-06-14

3.  Design and conduct of Caudwell Xtreme Everest: an observational cohort study of variation in human adaptation to progressive environmental hypoxia.

Authors:  Denny Z H Levett; Daniel S Martin; Mark H Wilson; Kay Mitchell; Sundeep Dhillon; Fabio Rigat; Hugh E Montgomery; Monty G Mythen; Michael P W Grocott
Journal:  BMC Med Res Methodol       Date:  2010-10-21       Impact factor: 4.615

4.  Incidence and Symptoms of High Altitude Illness in South Pole Workers: Antarctic Study of Altitude Physiology (ASAP).

Authors:  Paul J Anderson; Andrew D Miller; Kathy A O'Malley; Maile L Ceridon; Kenneth C Beck; Christina M Wood; Heather J Wiste; Joshua J Mueller; Jacob B Johnson; Bruce D Johnson
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2011-05-29

5.  Design and conduct of Xtreme Everest 2: An observational cohort study of Sherpa and lowlander responses to graduated hypobaric hypoxia.

Authors:  Edward Gilbert-Kawai; Adam Sheperdigian; Thomas Adams; Kay Mitchell; Martin Feelisch; Andrew Murray; Mark Peters; Grace Gilbert-Kawai; Hugh Montgomery; Denny Levett; Rajendra Kumar; Michael Mythen; Michael Grocott; Daniel Martin
Journal:  F1000Res       Date:  2015-04-10

6.  Curiositas.

Authors: 
Journal:  Ulster Med J       Date:  2016-01

7.  Metabolic adaptation of skeletal muscle to high altitude hypoxia: how new technologies could resolve the controversies.

Authors:  Andrew J Murray
Journal:  Genome Med       Date:  2009-12-18       Impact factor: 11.117

8.  Xtreme Everest 2: unlocking the secrets of the Sherpa phenotype?

Authors:  Daniel S Martin; Edward Gilbert-Kawai; Denny Zh Levett; Kay Mitchell; Rajendra Kumar Bc; Michael G Mythen; Michael Pw Grocott
Journal:  Extrem Physiol Med       Date:  2013-10-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.